The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review

• Published in: International journal of molecular sciences 2023-04, Vol.24 (8), p.7184
• Main Authors: Bica, Ioana-Cristina, Pietroșel, Valeria-Anca, Salmen, Teodor, Diaconu, Cosmina-Theodora, Fierbinteanu Braticevici, Carmen, Stoica, Roxana-Adriana, Suceveanu, Andra Iulia, Pantea Stoian, Anca
• Format: Article
• Language: English
• Subjects: Analysis; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Care and treatment; Complications and side effects; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes therapy; Fatty acids; GLP-1 RA; Glucagon-Like Peptide-1 Receptor - agonists; holistic approach; Humans; Hypoglycemic agents; Hypoglycemic Agents - adverse effects; Liraglutide - therapeutic use; Metformin - therapeutic use; Microbiota; Microbiota (Symbiotic organisms); Review; SGLT-2i; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Type 2 diabetes; type 2 diabetes mellitus
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24087184

As the pathophysiologic mechanisms of type 2 diabetes mellitus (T2DM) are discovered, there is a switch from glucocentric to a more comprehensive, patient-centered management. The holistic approach considers the interlink between T2DM and its complications, finding the best therapies for minimizing the cardiovascular (CV) or renal risk and benefitting from the treatment's pleiotropic effects. Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) fit best in the holistic approach because of their effects in reducing the risk of CV events and obtaining better metabolic control. Additionally, research on the SGLT-2i and GLP-1 RA modification of gut microbiota is accumulating. The microbiota plays a significant role in the relation between diet and CV disease because some intestinal bacteria lead to an increase in short-chain fatty acids (SCFA) and consequent positive effects. Thus, our review aims to describe the relation between antidiabetic non-insulin therapy (SGLT-2i and GLP-1 RA) with CV-proven benefits and the gut microbiota in patients with T2DM. We identified five randomized clinical trials including dapagliflozin, empagliflozin, liraglutide, and loxenatide, with different results. There were differences between empagliflozin and metformin regarding the effects on microbiota despite similar glucose control in both study groups. One study demonstrated that liraglutide induced gut microbiota alterations in patients with T2DM treated initially with metformin, but another failed to detect any differences when the same molecule was compared with sitagliptin. The established CV and renal protection that the SGLT-2i and GLP-1 RA exert could be partly due to their action on gut microbiota. The individual and cumulative effects of antidiabetic drugs on gut microbiota need further research.